60 Degrees Pharmaceuticals (SXTP) Cash from Investing Activities (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Cash from Investing Activities of $1.2 million for Q1 2026, down 29.89% year-over-year from $1.7 million in Q1 2025, and up 187.09% quarter-over-quarter from -$1.4 million in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Cash from Investing Activities (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Cash from Investing Activities for 5 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 29.89% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at -$254042.0 (down 43.7% YoY), while the FY2025 annual figure was $254916.0, up 113.49% from the prior year.
- Cash from Investing Activities improved to $1.2 million in Q1 2026 per SXTP's latest filing, from -$1.4 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $1.7 million in Q1 2025 and bottomed at -$1.7 million in Q3 2024.
- Historically, Cash from Investing Activities has averaged -$40916.8 across 5 years, with a median of -$25487.0 in 2025.
- On a YoY basis, Cash from Investing Activities climbed as much as 17447.85% in 2025 and fell as far as 65220.83% in 2025.
- 60 Degrees Pharmaceuticals' Cash from Investing Activities stood at -$58645.0 in 2022, then slipped by 13.5% to -$66562.0 in 2023, then surged by 96.85% to -$2098.0 in 2024, then tumbled by 65220.83% to -$1.4 million in 2025, then surged by 187.09% to $1.2 million in 2026.
- Business Quant data shows SXTP's Cash from Investing Activities at $1.2 million in Q1 2026, -$1.4 million in Q4 2025, and -$25487.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | -85,984.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.19 Mn |
| Mar 31, 2026 | 1.19 Mn |
| Dec 31, 2025 | -1.37 Mn |
| Dec 31, 2025 | -1.37 Mn |
| Sep 30, 2025 | -25,487.00 |
| Sep 30, 2025 | -25,487.00 |
| Jun 30, 2025 | -51,684.00 |
| Jun 30, 2025 | -51,684.00 |
| Mar 31, 2025 | 1.70 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | -2,098.00 |
| Dec 31, 2024 | -2,098.00 |
| Sep 30, 2024 | -1.75 Mn |
| Sep 30, 2024 | -1.75 Mn |
| Jun 30, 2024 | -130,559.00 |
| Jun 30, 2024 | -130,559.00 |
| Mar 31, 2024 | -9,814.00 |
| Mar 31, 2024 | -9,814.00 |
| Dec 31, 2023 | -66,562.00 |
| Dec 31, 2023 | -66,562.00 |